➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
AstraZeneca
Boehringer Ingelheim
McKinsey
Moodys

Last Updated: September 24, 2020

DrugPatentWatch Database Preview

Litigation Details for SUCAMPO AG v. DR. REDDY'S LABORATORIES, INC. (D.N.J. 2014)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in SUCAMPO AG v. DR. REDDY'S LABORATORIES, INC.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for SUCAMPO AG v. DR. REDDY'S LABORATORIES, INC. (D.N.J. 2014)

Date Filed Document No. Description Snippet Link To Document
2015-01-26 16 Sucampo AG owns United States Patent No. 6,414,016 (“the ‘016 patent”) titled “Anti-Constipation Composition… The claims of the patents-in-suit, United States Patents 6,414,016, 8,071,613, 7,795,312, 8,097,653… enforceable claim of the patents-in-suit, United States Patents 6,414,016, 8,071,613, 7,795,312, 8,… Sucampo AG owns United States Patent No. 6,414,016 (“the ‘016 patent”), titled “Anti-Constipation Composition…action alleging infringement of United States Patents 6,414,016, 8,071,613, 7,795,312, 8,097,653, 8,389,542 External link to document
2015-11-30 45 for the term “patient” in the claims of U.S. 8,071,613, please tell us whether Plaintiffs agree that …of “plain meaning,” or, as required by the Local Patent Rules, Plaintiffs must actually disclose to DRL… Plaintiffs’ October 1 Disclosures under Local Patent Rule 4.2(a) recite “plain meaning” as Plaintiffs…disputed claim terms. Disclosures under Local Patent Rule 4.2(c) are due October 15. So that the parties…;Moses, David L.'; Madge Thomas Cc: Amitiza Patent Litigation; Csepes, Peter; 'William F. Cavanaugh External link to document
2016-03-01 49 concerning U.S. Patent No. 7,682,628 (“’628 Patent”); U.S. Patent No. 8,242,131 (“’131 Patent”); and U.S.… 506 U.S. Patent No. 7,682,628 Term Identified for Construction…claim terms is as follows: U.S. Patent No. 7,682,628 Term Identified for …U.S. Patent No. 8,252,809 (“’809 Patent”). I. Construction of Claim Terms on which the Parties Agree…Final Joint Claim Chart for U.S. Patent No. 8,445,524 (“the ‘524 patent”) External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Mallinckrodt
Medtronic
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.